Slideshow

Reduced Risk for Cardiovascular Events with Albiglutide in T2DM

Author(s):

Gregory M. Weiss, MD

Can albiglutide reduce the risk of cardiovascular events in T2DM patients? A new study sheds some light. 

Reference: Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018. 

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Related Content
Serum Uric Acid Levels Linked to Risk of Dyslipidemia in Type 2 Diabetes | Image Credit: National Cancer Institute
January 7th 2025

Serum Uric Acid Levels Linked to Risk of Dyslipidemia in Type 2 Diabetes

Connor Iapoce
Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas | Image Credit: HCPLive
January 6th 2025

Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
GLP-1 RA Discontinuations Frequent in People with Obesity Without Diabetes| Image Credit: Kenny Eliason/Unsplash
January 3rd 2025

GLP-1 RA Discontinuations Frequent in People with Obesity Without Diabetes

Connor Iapoce
Diabetes Dialogue: Insights on INHALE-1 and CATALYST Trials | Image Credit: HCPLive
January 2nd 2025

Diabetes Dialogue: Insights on INHALE-1 and CATALYST Trials

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Podcasts & Shows Year in Review: 2024 | Image Credit: HCPLive
December 26th 2024

HCPLive Year in Review: Top Podcasts & Shows for 2024

Connor Iapoce
FDA Logo | Credit: US Food and Drug Administration
December 23rd 2024

FDA Approves Generic Once-Daily GLP-1 RA for Type 2 Diabetes in Pediatric, Adult Patients

Patrick Campbell
© 2025 MJH Life Sciences

All rights reserved.